Due to the high immunogenicity and strong T cell infiltration of RCC,5, 6 programmed cell death‐1/ programmed cell death‐ligand 1 (PD‐1/PD‐L1) monoclonal antibodies (mAbs), which can strengthen cellular immunity, have been gradually applied in the treatment of aRCC as monotherapy recently and achieved considerable efficacy and acceptable safety, especially in ccRCC.7 This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.